SIMILAR PATTERNS OF AMINO ACIDS FOR 3QXV_B_MTXB2000_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1g6v	ANTIBODY HEAVY CHAIN (Camelus dromedarius)	PF07686 (V-set)	5	VAL K 802 ALA K 824 MET K 834 VAL K 877 TYR K 915	None	0.83A	3qxvB-1g6vK: 20.3	3qxvB-1g6vK: 69.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1i3u	ANTIBODY VHH LAMA DOMAIN (Lama glama)	PF07686 (V-set)	5	ALA A 24 ARG A 77 VAL A 84 ALA A 103 TYR A 118	None None None None CGN A 1 ( 4.0A)	0.84A	3qxvB-1i3uA: 20.9	3qxvB-1i3uA: 59.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1kxt	IMMUNOGLOBULIN VHH FRAGMENT (Camelus dromedarius)	PF07686 (V-set)	5	VAL B 2 ALA B 24 ARG B 71 ALA B 94 TYR B 102	None	0.94A	3qxvB-1kxtB: 19.2	3qxvB-1kxtB: 68.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1kxt	IMMUNOGLOBULIN VHH FRAGMENT (Camelus dromedarius)	PF07686 (V-set)	5	VAL B 2 ALA B 24 MET B 34 ALA B 94 TYR B 102	None	0.96A	3qxvB-1kxtB: 19.2	3qxvB-1kxtB: 68.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1pz5	HEAVY CHAIN OF FAB (SYA/J6) (Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 ARG B 71 VAL B 78 TYR B 102	None	1.02A	3qxvB-1pz5B: 20.1	3qxvB-1pz5B: 51.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1qd0	VHH-R2 ANTI-RR6 ANTIBODY (Lama glama)	PF07686 (V-set)	5	MET A 37 ARG A 75 VAL A 82 ALA A 101 TYR A 117	None	0.99A	3qxvB-1qd0A: 19.8	3qxvB-1qd0A: 71.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1sbs	MONOCLONAL ANTIBODY 3A2 (Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	5	VAL H 2 MET H 34 ARG H 74 VAL H 81 TYR H 112	None	0.87A	3qxvB-1sbsH: 19.8	3qxvB-1sbsH: 52.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t66	IMMUNOGLOBULIN HEAVY CHAIN (Mus musculus)	no annotation	6	VAL H 2 ALA H 24 MET H 34 ARG H 74 VAL H 81 TYR H 107	None	0.91A	3qxvB-1t66H: 19.2	3qxvB-1t66H: 31.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1x9q	4M5.3 ANTI-FLUORESCEIN SINGLE CHAIN ANTIBODY FRAGMENT (Homo sapiens)	PF07686 (V-set)	5	VAL A 153 MET A 185 ARG A 225 VAL A 232 TYR A 258	None	0.72A	3qxvB-1x9qA: 13.8	3qxvB-1x9qA: 29.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2x6m	HEAVY CHAIN VARIABLE DOMAIN FROM DROMEDARY (Camelus dromedarius)	PF07686 (V-set)	5	ALA A 24 MET A 34 VAL A 80 ALA A 99 TYR A 115	None	0.76A	3qxvB-2x6mA: 21.5	3qxvB-2x6mA: 70.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xa3	LLAMA HEAVY CHAIN ANTIBODY D7 (Lama glama)	PF07686 (V-set)	5	SER A 29 MET A 34 VAL A 78 ALA A 94 TYR A 102	SO4 A1114 (-2.7A) None None None None	0.76A	3qxvB-2xa3A: 20.9	3qxvB-2xa3A: 69.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3g9a	MINIMIZER (Camelus dromedarius)	PF07686 (V-set)	6	ALA B 24 MET B 34 ARG B 71 VAL B 78 ALA B 94 TYR B 102	None	0.69A	3qxvB-3g9aB: 19.7	3qxvB-3g9aB: 64.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3if1	IMMUNOGLOBULIN HEAVY CHAIN (IGG2A) (Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	5	VAL B 2 ALA B 24 MET B 34 ARG B 71 TYR B 102	None	0.74A	3qxvB-3if1B: 19.6	3qxvB-3if1B: 32.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3k7u	ANTIBODY (Lama glama)	PF07686 (V-set)	5	MET A 34 ARG A 72 VAL A 79 ALA A 98 TYR A 111	None	0.47A	3qxvB-3k7uA: 22.2	3qxvB-3k7uA: 73.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ln9	IMMUNOGLOBULIN HEAVY CHAIN ANTIBODY VARIABLE DOMAIN B10 (Camelidae)	PF07686 (V-set)	6	VAL A 2 ALA A 24 ARG A 72 VAL A 79 ALA A 98 TYR A 113	None None None None None GOL A 137 (-4.8A)	0.92A	3qxvB-3ln9A: 19.4	3qxvB-3ln9A: 67.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qxu	ANTI-METHOTREXATE CDR1-3 GRAFT (Lama glama)	PF07686 (V-set)	6	SER A 30 TRP A 34 MET A 36 VAL A 81 ALA A 100 TYR A 120	None	1.49A	3qxvB-3qxuA: 24.1	3qxvB-3qxuA: 96.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qxu	ANTI-METHOTREXATE CDR1-3 GRAFT (Lama glama)	PF07686 (V-set)	7	SER A 31 TRP A 34 MET A 36 ARG A 74 VAL A 81 ALA A 100 TYR A 120	None	1.43A	3qxvB-3qxuA: 24.1	3qxvB-3qxuA: 96.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qxu	ANTI-METHOTREXATE CDR1-3 GRAFT (Lama glama)	PF07686 (V-set)	7	VAL A 4 ALA A 26 SER A 30 MET A 36 VAL A 81 ALA A 100 TYR A 120	None	0.89A	3qxvB-3qxuA: 24.1	3qxvB-3qxuA: 96.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qxu	ANTI-METHOTREXATE CDR1-3 GRAFT (Lama glama)	PF07686 (V-set)	8	VAL A 4 ALA A 26 SER A 31 MET A 36 ARG A 74 VAL A 81 ALA A 100 TYR A 120	None	0.91A	3qxvB-3qxuA: 24.1	3qxvB-3qxuA: 96.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qyc	VH DOMAIN OF IGG MOLECULE (Homo sapiens)	PF07686 (V-set)	5	VAL A 4 ALA A 26 MET A 36 ARG A 74 VAL A 81	None	0.86A	3qxvB-3qycA: 20.1	3qxvB-3qycA: 61.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3r0m	LLAMA VHH A12 (Lama glama)	PF07686 (V-set)	5	ALA A 24 SER A 29 MET A 34 VAL A 78 ALA A 94	None SO4 A 131 (-2.7A) None None None	0.93A	3qxvB-3r0mA: 21.4	3qxvB-3r0mA: 70.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3sge	HEAVY CHAIN (Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	5	VAL H 2 ALA H 24 MET H 34 ARG H 74 TYR H 104	None	0.88A	3qxvB-3sgeH: 20.1	3qxvB-3sgeH: 37.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3stb	SINGLE DOMAIN ANTIBODY VHH (Lama glama)	PF07686 (V-set)	5	ALA A 26 MET A 36 ARG A 73 VAL A 80 ALA A 99	None	0.67A	3qxvB-3stbA: 22.0	3qxvB-3stbA: 70.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4b41	ANTIBODY G7 (Lama glama)	PF07686 (V-set)	5	VAL A 2 ALA A 24 MET A 34 VAL A 78 ALA A 97	None	0.93A	3qxvB-4b41A: 18.6	3qxvB-4b41A: 72.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4dka	SINGLE DOMAIN ANTIBODY VHH (Lama glama)	PF07686 (V-set)	6	ALA A 24 MET A 34 ARG A 72 VAL A 79 ALA A 98 TYR A 116	None	0.75A	3qxvB-4dkaA: 22.0	3qxvB-4dkaA: 73.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4dka	SINGLE DOMAIN ANTIBODY VHH (Lama glama)	PF07686 (V-set)	6	ALA A 24 SER A 30 MET A 34 ARG A 72 VAL A 79 ALA A 98	None	1.39A	3qxvB-4dkaA: 22.0	3qxvB-4dkaA: 73.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4eig	CA1698 CAMEL ANTIBODY FRAGMENT (Lama glama)	PF07686 (V-set)	6	ALA B 24 MET B 34 ARG B 71 VAL B 78 ALA B 97 TYR B 106	None	0.71A	3qxvB-4eigB: 20.1	3qxvB-4eigB: 66.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4fhb	NB179 (Lama glama)	PF07686 (V-set)	5	MET D 34 ARG D 72 VAL D 79 ALA D 98 TYR D 118	None	0.52A	3qxvB-4fhbD: 21.2	3qxvB-4fhbD: 71.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4gft	NANOBODY (Lama glama)	PF07686 (V-set)	5	MET B 36 ARG B 74 VAL B 81 ALA B 100 TYR B 115	None None None None PCA B 2 ( 3.9A)	0.35A	3qxvB-4gftB: 22.2	3qxvB-4gftB: 66.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hem	ANTI-BASEPLATE TP901-1 LLAMA VHH 02 (Lama glama)	PF07686 (V-set)	6	ALA E 24 MET E 34 ARG E 72 VAL E 79 ALA E 98 TYR E 112	None	0.68A	3qxvB-4hemE: 22.9	3qxvB-4hemE: 73.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hxa	13D9 FAB HEAVY CHAIN (Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	5	VAL H 2 MET H 34 ARG H 71 VAL H 78 TYR H 102	None	0.88A	3qxvB-4hxaH: 20.3	3qxvB-4hxaH: 53.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4krm	NANOBODY/VHH DOMAIN 7D12 (Lama glama)	PF07686 (V-set)	5	ALA B 24 MET B 34 VAL B 79 ALA B 98 TYR B 113	None	0.71A	3qxvB-4krmB: 23.4	3qxvB-4krmB: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4krm	NANOBODY/VHH DOMAIN 7D12 (Lama glama)	PF07686 (V-set)	5	MET B 34 ARG B 72 VAL B 79 ALA B 98 TYR B 113	None	0.38A	3qxvB-4krmB: 23.4	3qxvB-4krmB: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4krm	NANOBODY/VHH DOMAIN 7D12 (Lama glama)	PF07686 (V-set)	5	SER B 29 MET B 34 VAL B 79 ALA B 98 TYR B 113	None	0.92A	3qxvB-4krmB: 23.4	3qxvB-4krmB: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lde	CAMELID ANTIBODY FRAGMENT (Lama glama)	PF07686 (V-set)	5	VAL B 2 MET B 34 ARG B 71 VAL B 78 TYR B 109	None	0.75A	3qxvB-4ldeB: 19.2	3qxvB-4ldeB: 68.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lhq	CAMELID NANOBODY (Vicugna pacos)	PF07686 (V-set)	5	ALA B 24 SER B 28 MET B 34 ARG B 72 VAL B 79	None	0.90A	3qxvB-4lhqB: 21.6	3qxvB-4lhqB: 63.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4nc1	A20.1 VHH (Lama glama)	PF07686 (V-set)	7	VAL C 9 ALA C 31 MET C 41 ARG C 79 VAL C 86 ALA C 105 TYR C 119	None	0.93A	3qxvB-4nc1C: 22.1	3qxvB-4nc1C: 70.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4nc2	B39 VHH (Lama glama)	PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 ARG B 71 ALA B 97 TYR B 111	None	0.82A	3qxvB-4nc2B: 22.8	3qxvB-4nc2B: 70.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ouo	ANTI BLA G 1 SCFV (Gallus gallus)	PF07686 (V-set)	5	VAL A 116 ALA A 138 MET A 148 ARG A 185 VAL A 192	None	0.92A	3qxvB-4ouoA: 13.3	3qxvB-4ouoA: 27.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4p2c	NANOBODY 1, ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION (Lama glama)	PF07686 (V-set)	6	VAL G 2 MET G 34 ARG G 71 VAL G 78 ALA G 97 TYR G 111	None	0.59A	3qxvB-4p2cG: 18.9	3qxvB-4p2cG: 70.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4qlr	LLAMA NANOBODY N02 VH DOMAIN (Lama glama)	PF07686 (V-set)	5	ALA A 24 ARG A 72 VAL A 79 ALA A 98 TYR A 113	None	0.78A	3qxvB-4qlrA: 22.3	3qxvB-4qlrA: 69.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4qo1	NB139 NANOBODY AGAINST THE DNA-BINDING DOMAIN OF P53 (Lama glama)	PF07686 (V-set)	6	ALA A 25 MET A 35 ARG A 73 VAL A 80 ALA A 99 TYR A 113	None	0.62A	3qxvB-4qo1A: 21.3	3qxvB-4qo1A: 62.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4tvs	VHH DOMAIN BS-1 (Vicugna pacos)	PF05609 (LAP1C)	5	ALA a 25 ARG a 73 VAL a 80 ALA a 99 TYR a 117	None	0.80A	3qxvB-4tvsa: 22.3	3qxvB-4tvsa: 72.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4w6y	NANOBODY NBFEDF9 (Lama glama)	PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 VAL B 79 ALA B 98 TYR B 118	None	0.96A	3qxvB-4w6yB: 21.0	3qxvB-4w6yB: 69.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4weu	ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION (Lama glama)	PF07686 (V-set)	6	VAL D 802 ALA D 824 MET D 834 ARG D 872 ALA D 898 TYR D 910	None	0.69A	3qxvB-4weuD: 22.1	3qxvB-4weuD: 72.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4x8j	12F4 FAB HEAVY CHAIN (Mus musculus)	no annotation	5	VAL H 2 MET H 34 ARG H 74 VAL H 81 TYR H 104	None None None None 2PE H 302 ( 4.6A)	0.83A	3qxvB-4x8jH: 15.4	3qxvB-4x8jH: 33.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xt1	NANOBODY 7 (Vicugna pacos)	PF07686 (V-set)	6	VAL C 2 ALA C 24 MET C 34 VAL C 78 ALA C 97 TYR C 107	None	0.94A	3qxvB-4xt1C: 18.9	3qxvB-4xt1C: 68.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4yga	VHH-1B7 (Vicugna pacos)	PF07686 (V-set)	5	VAL B 3 ALA B 25 ARG B 73 VAL B 80 ALA B 99	None	0.63A	3qxvB-4ygaB: 20.2	3qxvB-4ygaB: 60.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4zfo	J22.9-XI FAB, HEAVY CHAIN (Mus musculus)	no annotation	5	VAL H 2 ALA H 24 MET H 34 ARG H 72 TYR H 109	None	0.90A	3qxvB-4zfoH: 19.0	3qxvB-4zfoH: 37.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5a2k	IG LAMBDA-1 CHAIN V REGION S43 (Mus musculus)	PF07686 (V-set)	6	VAL H 2 ALA H 24 MET H 34 ARG H 71 VAL H 78 TYR H 102	None	0.80A	3qxvB-5a2kH: 19.8	3qxvB-5a2kH: 29.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5aum	HEAVY CHAIN OF FAB FRAGMENT (Rattus)	no annotation	6	VAL H 2 ALA H 24 MET H 34 ARG H 71 VAL H 78 ALA H 94	None	0.70A	3qxvB-5aumH: 19.7	3qxvB-5aumH: 38.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5b6f	ANTI-LEUKOTRIENE C4 MONOCLONAL ANTIBODY IMMUNOGLOBULIN GAMMA1 HEAVY CHAIN (Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	5	VAL B 21 ALA B 43 MET B 53 ARG B 93 VAL B 100	None	0.74A	3qxvB-5b6fB: 19.3	3qxvB-5b6fB: 35.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fwo	NANOBODY (Lama glama)	PF07686 (V-set)	5	VAL A 2 ALA A 24 MET A 34 VAL A 78 TYR A 102	None	0.91A	3qxvB-5fwoA: 21.5	3qxvB-5fwoA: 68.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fwo	NANOBODY (Lama glama)	PF07686 (V-set)	6	VAL A 2 MET A 34 ARG A 71 VAL A 78 ALA A 94 TYR A 102	None	0.60A	3qxvB-5fwoA: 21.5	3qxvB-5fwoA: 68.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5gxb	NANOBODY (Vicugna pacos)	PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 VAL B 79 ALA B 98 TYR B 118	None	1.10A	3qxvB-5gxbB: 20.7	3qxvB-5gxbB: 68.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hm1	LAMA VHH ANTIBODY 2E7 (Lama glama)	PF07686 (V-set)	5	VAL A 2 ALA A 24 VAL A 78 ALA A 94 TYR A 102	None	0.64A	3qxvB-5hm1A: 18.6	3qxvB-5hm1A: 68.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hvf	VHH-I83 (Vicugna pacos)	PF07686 (V-set)	5	VAL B 2 ALA B 24 ARG B 70 VAL B 77 TYR B 108	None	0.88A	3qxvB-5hvfB: 18.7	3qxvB-5hvfB: 69.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hvf	VHH-I83 (Vicugna pacos)	PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 VAL B 77 ALA B 96 TYR B 108	None	1.01A	3qxvB-5hvfB: 18.7	3qxvB-5hvfB: 69.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5iml	NANOBODY (Camelidae)	PF07686 (V-set)	5	MET B 33 ARG B 71 VAL B 78 ALA B 97 TYR B 113	None	0.35A	3qxvB-5imlB: 23.7	3qxvB-5imlB: 75.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j1s	VHH DOMAIN BS-2 (Vicugna pacos)	PF07686 (V-set)	5	ALA C 25 MET C 35 ARG C 72 VAL C 79 ALA C 98	None	0.94A	3qxvB-5j1sC: 19.4	3qxvB-5j1sC: 66.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j1s	VHH DOMAIN BS-2 (Vicugna pacos)	PF07686 (V-set)	6	VAL C 3 ALA C 25 MET C 35 VAL C 79 ALA C 98 TYR C 112	None	0.74A	3qxvB-5j1sC: 19.4	3qxvB-5j1sC: 66.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j56	VHH SINGLE CHAIN ANTIBODY V1C7 (Vicugna pacos)	PF07686 (V-set)	5	ALA B 24 ARG B 76 VAL B 83 ALA B 102 TYR B 117	None	0.67A	3qxvB-5j56B: 20.5	3qxvB-5j56B: 67.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5ja8	NANOBODY 2 (Lama glama)	PF07686 (V-set)	5	VAL B 3 ALA B 25 ARG B 73 VAL B 80 ALA B 99	None	0.69A	3qxvB-5ja8B: 19.9	3qxvB-5ja8B: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5jqh	NANOBODY60, NB60 (Lama glama)	no annotation	5	MET D 34 ARG D 71 VAL D 78 ALA D 97 TYR D 108	None	0.88A	3qxvB-5jqhD: 19.1	3qxvB-5jqhD: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5kel	C2G4 VARIABLE FAB DOMAIN HEAVY CHAIN (Homo sapiens)	PF07686 (V-set)	5	ALA H 24 MET H 34 ARG H 71 VAL H 78 TYR H 102	None	0.88A	3qxvB-5kelH: 17.1	3qxvB-5kelH: 51.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lhq	CAMELID-DERIVED ANTIBODY FRAGMENT NB7 (Vicugna pacos)	PF07686 (V-set)	6	VAL B 2 ALA B 24 ARG B 72 VAL B 79 ALA B 98 TYR B 122	None	0.54A	3qxvB-5lhqB: 21.8	3qxvB-5lhqB: 64.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lmj	NANOBODY (Lama glama)	PF07686 (V-set)	6	ALA A 24 MET A 34 ARG A 71 VAL A 78 ALA A 94 TYR A 102	None	0.98A	3qxvB-5lmjA: 20.4	3qxvB-5lmjA: 73.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lmj	NANOBODY (Lama glama)	PF07686 (V-set)	6	VAL A 2 ALA A 24 ARG A 71 VAL A 78 ALA A 94 TYR A 102	None	0.81A	3qxvB-5lmjA: 20.4	3qxvB-5lmjA: 73.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lwf	CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-G10S (Lama glama)	no annotation	6	VAL C 5 ALA C 27 MET C 37 ARG C 75 ALA C 101 TYR C 117	None None None None None ACT C 202 (-4.4A)	0.74A	3qxvB-5lwfC: 21.1	3qxvB-5lwfC: 68.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lwf	CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-G10S (Lama glama)	no annotation	6	VAL C 5 MET C 37 ARG C 75 VAL C 82 ALA C 101 TYR C 117	None None None None None ACT C 202 (-4.4A)	0.77A	3qxvB-5lwfC: 21.1	3qxvB-5lwfC: 68.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5mwn	LLAMA NANOBODY RAISED AGAINST TSSK, NBK27 (Lama glama)	PF07686 (V-set)	5	VAL N 2 ALA N 24 ARG N 71 VAL N 78 ALA N 97	None	0.85A	3qxvB-5mwnN: 18.2	3qxvB-5mwnN: 67.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5mwn	LLAMA NANOBODY RAISED AGAINST TSSK, NBK27 (Lama glama)	PF07686 (V-set)	5	VAL N 2 ALA N 24 MET N 34 VAL N 78 ALA N 97	None	0.86A	3qxvB-5mwnN: 18.2	3qxvB-5mwnN: 67.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o02	NANOBODY (VHH) NANO-4 (Vicugna pacos)	PF07686 (V-set)	5	VAL C 2 ALA C 24 ARG C 72 ALA C 98 TYR C 113	None	0.93A	3qxvB-5o02C: 21.3	3qxvB-5o02C: 68.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o02	NANOBODY (VHH) NANO-4 (Vicugna pacos)	PF07686 (V-set)	5	VAL C 2 MET C 34 ARG C 72 ALA C 98 TYR C 113	None	0.59A	3qxvB-5o02C: 21.3	3qxvB-5o02C: 68.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o04	NANOBODY (VHH) NANO-26 (Vicugna pacos)	PF07686 (V-set)	5	VAL E 2 ALA E 24 ARG E 71 VAL E 78 TYR E 104	None	0.83A	3qxvB-5o04E: 18.5	3qxvB-5o04E: 65.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o0w	NB474 (Vicugna pacos)	PF07686 (V-set)	5	VAL E 2 ALA E 24 ARG E 76 VAL E 83 TYR E 126	None	0.81A	3qxvB-5o0wE: 20.4	3qxvB-5o0wE: 64.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o8f	NANOBODY NB25 (Lama glama)	no annotation	5	MET L 34 ARG L 72 VAL L 79 ALA L 98 TYR L 114	None	0.53A	3qxvB-5o8fL: 21.6	3qxvB-5o8fL: 68.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5o8r	L-LYSINE 6-MONOOXYGENASE INVOLVED IN DESFERRIOXAMINE BIOSYNTHESIS (Erwinia amylovora)	no annotation	5	VAL A 33 SER A 136 VAL A 376 ALA A 149 TYR A 6	None	1.01A	3qxvB-5o8rA: undetectable	3qxvB-5o8rA: 19.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5u3j	DH511.1 HEAVY CHAIN (Homo sapiens)	PF07654 (C1-set) PF07686 (V-set)	5	VAL H 2 ALA H 24 MET H 34 ARG H 71 ALA H 94	None	0.85A	3qxvB-5u3jH: 19.5	3qxvB-5u3jH: 54.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5uk4	ANTI-VESICULAR STOMATITIS VIRUS N VHH (Vicugna pacos)	no annotation	5	VAL p 2 ALA p 24 ARG p 72 ALA p 98 TYR p 114	None	0.98A	3qxvB-5uk4p: 21.2	3qxvB-5uk4p: 71.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5uk4	ANTI-VESICULAR STOMATITIS VIRUS N VHH (Vicugna pacos)	no annotation	6	VAL p 2 MET p 34 ARG p 72 VAL p 79 ALA p 98 TYR p 114	None	0.73A	3qxvB-5uk4p: 21.2	3qxvB-5uk4p: 71.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5ukb	ANTI-VESICULAR STOMATITIS VIRUS N VHH (Vicugna pacos)	no annotation	5	ALA d 24 ARG d 72 VAL d 79 ALA d 98 TYR d 113	None	0.77A	3qxvB-5ukbd: 22.4	3qxvB-5ukbd: 70.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vxj	SINGLE-DOMAIN ANTIBODY JMK-E3 (Vicugna pacos)	no annotation	6	VAL B 2 MET B 34 ARG B 72 VAL B 79 ALA B 98 TYR B 108	None	0.79A	3qxvB-5vxjB: 19.1	3qxvB-5vxjB: 63.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vxl	SINGLE-DOMAIN ANTIBODY JPS-G3 (Vicugna pacos)	no annotation	5	ALA B 24 MET B 34 ARG B 73 ALA B 99 TYR B 106	None	0.71A	3qxvB-5vxlB: 20.1	3qxvB-5vxlB: 66.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vxl	SINGLE-DOMAIN ANTIBODY JPS-G3 (Vicugna pacos)	no annotation	5	MET B 34 ARG B 73 VAL B 80 ALA B 99 TYR B 106	None	0.57A	3qxvB-5vxlB: 20.1	3qxvB-5vxlB: 66.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5w1g	CR1-07 FAB HEAVY CHAIN (Homo sapiens)	no annotation	5	VAL H 2 ALA H 24 MET H 34 ARG H 72 TYR H 113	None	0.88A	3qxvB-5w1gH: 21.4	3qxvB-5w1gH: 40.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wb1	ENVELOPE PROTEIN US28, NANOBODY 7 FUSION PROTEIN (Human betaherpesvirus 5; Lama glama)	no annotation	6	VAL A1002 ALA A1024 MET A1034 VAL A1078 ALA A1097 TYR A1107	None	1.00A	3qxvB-5wb1A: 17.9	3qxvB-5wb1A: 15.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5wb2	NANOBODY B1 (synthetic construct)	no annotation	5	ALA D 24 ARG D 72 VAL D 79 ALA D 98 TYR D 118	None	0.96A	3qxvB-5wb2D: 18.6	3qxvB-5wb2D: 68.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5x0t	6H8 FAB FRAGMENT HEAVY CHAIN (Mus musculus)	no annotation	6	VAL A 21 ALA A 43 MET A 53 ARG A 93 VAL A 100 TYR A 124	None	0.85A	3qxvB-5x0tA: 19.9	3qxvB-5x0tA: 31.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5yy5	- (-)	no annotation	5	VAL C 2 ALA C 24 MET C 34 ARG C 71 TYR C 97	None	0.89A	3qxvB-5yy5C: 19.3	3qxvB-5yy5C: undetectable
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6c5w	NANOBODY (Escherichia coli)	no annotation	5	VAL C 2 MET C 34 VAL C 78 ALA C 97 TYR C 107	None	0.87A	3qxvB-6c5wC: 19.1	3qxvB-6c5wC: 72.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6dbe	NANOBODY VHH R303 (Lama glama)	no annotation	5	ALA A 24 MET A 34 VAL A 79 ALA A 98 TYR A 107	None	0.72A	3qxvB-6dbeA: 20.5	3qxvB-6dbeA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6dbe	NANOBODY VHH R303 (Lama glama)	no annotation	6	SER A 30 MET A 34 ARG A 72 VAL A 79 ALA A 98 TYR A 107	None	1.21A	3qxvB-6dbeA: 20.5	3qxvB-6dbeA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6dbe	NANOBODY VHH R303 (Lama glama)	no annotation	5	VAL A 2 ALA A 24 MET A 34 VAL A 79 TYR A 107	None	0.84A	3qxvB-6dbeA: 20.5	3qxvB-6dbeA: undetectable
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6ehg	HC3NB1 (Lama glama)	no annotation	5	ALA C 24 MET C 34 ARG C 72 VAL C 79 ALA C 98	None	0.74A	3qxvB-6ehgC: 22.3	3qxvB-6ehgC: 57.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6ehg	HC3NB1 (Lama glama)	no annotation	5	MET C 34 ARG C 72 VAL C 79 ALA C 98 TYR C 112	None	0.50A	3qxvB-6ehgC: 22.3	3qxvB-6ehgC: 57.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6ey0	LLAMA NANOBODY NB01 (Lama glama)	no annotation	5	MET E 34 ARG E 71 VAL E 78 ALA E 94 TYR E 102	None	0.78A	3qxvB-6ey0E: 21.3	3qxvB-6ey0E: 56.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6g8r	SHORT-CHAIN VARIABLE FRAGMENT (Homo sapiens)	no annotation	5	VAL A 2 ALA A 24 MET A 34 ARG A 72 TYR A 108	None	0.99A	3qxvB-6g8rA: 20.2	3qxvB-6g8rA: 62.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6gzp	NANOBODY (Lama glama)	no annotation	6	VAL A 2 ALA A 24 MET A 34 ARG A 71 ALA A 94 TYR A 102	None	0.83A	3qxvB-6gzpA: 21.8	3qxvB-6gzpA: undetectable
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	8fab	IGG1-LAMBDA HIL FAB (HEAVY CHAIN) (Homo sapiens)	PF07654 (C1-set) PF07686 (V-set)	5	VAL B 2 ALA B 24 MET B 34 ARG B 72 TYR B 110	None	0.96A	3qxvB-8fabB: 21.6	3qxvB-8fabB: 59.52

[["3QXV_B_MTXB2000_1","1g6v","Camelus dromedarius","ANTIBODY HEAVY CHAIN","PF07686(V-set)",5,"VAL K 802;ALA K 824;MET K 834;VAL K 877;TYR K 915","None","0.83A","3qxvB-1g6vK:20.3","3qxvB-1g6vK:69.53"],["3QXV_B_MTXB2000_1","1i3u","Lama glama","ANTIBODY VHH LAMA DOMAIN","PF07686(V-set)",5,"ALA A  24;ARG A  77;VAL A  84;ALA A 103;TYR A 118","None;None;None;None;CGN A   1 ( 4.0A)","0.84A","3qxvB-1i3uA:20.9","3qxvB-1i3uA:59.85"],["3QXV_B_MTXB2000_1","1kxt","Camelus dromedarius","IMMUNOGLOBULIN VHH FRAGMENT","PF07686(V-set)",5,"VAL B   2;ALA B  24;ARG B  71;ALA B  94;TYR B 102","None","0.94A","3qxvB-1kxtB:19.2","3qxvB-1kxtB:68.75"],["3QXV_B_MTXB2000_1","1kxt","Camelus dromedarius","IMMUNOGLOBULIN VHH FRAGMENT","PF07686(V-set)",5,"VAL B   2;ALA B  24;MET B  34;ALA B  94;TYR B 102","None","0.96A","3qxvB-1kxtB:19.2","3qxvB-1kxtB:68.75"],["3QXV_B_MTXB2000_1","1pz5","Mus musculus","HEAVY CHAIN OF FAB (SYA\/J6)","PF07654(C1-set);PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;ARG B  71;VAL B  78;TYR B 102","None","1.02A","3qxvB-1pz5B:20.1","3qxvB-1pz5B:51.52"],["3QXV_B_MTXB2000_1","1qd0","Lama glama","VHH-R2 ANTI-RR6 ANTIBODY","PF07686(V-set)",5,"MET A  37;ARG A  75;VAL A  82;ALA A 101;TYR A 117","None","0.99A","3qxvB-1qd0A:19.8","3qxvB-1qd0A:71.88"],["3QXV_B_MTXB2000_1","1sbs","Mus musculus","MONOCLONAL ANTIBODY 3A2","PF07654(C1-set);PF07686(V-set)",5,"VAL H   2;MET H  34;ARG H  74;VAL H  81;TYR H 112","None","0.87A","3qxvB-1sbsH:19.8","3qxvB-1sbsH:52.24"],["3QXV_B_MTXB2000_1","1t66","Mus musculus","IMMUNOGLOBULIN HEAVY CHAIN","no annotation",6,"VAL H   2;ALA H  24;MET H  34;ARG H  74;VAL H  81;TYR H 107","None","0.91A","3qxvB-1t66H:19.2","3qxvB-1t66H:31.43"],["3QXV_B_MTXB2000_1","1x9q","Homo sapiens","4M5.3 ANTI-FLUORESCEIN SINGLE CHAIN ANTIBODY FRAGMENT","PF07686(V-set)",5,"VAL A 153;MET A 185;ARG A 225;VAL A 232;TYR A 258","None","0.72A","3qxvB-1x9qA:13.8","3qxvB-1x9qA:29.95"],["3QXV_B_MTXB2000_1","2x6m","Camelus dromedarius","HEAVY CHAIN VARIABLE DOMAIN FROM DROMEDARY","PF07686(V-set)",5,"ALA A  24;MET A  34;VAL A  80;ALA A  99;TYR A 115","None","0.76A","3qxvB-2x6mA:21.5","3qxvB-2x6mA:70.54"],["3QXV_B_MTXB2000_1","2xa3","Lama glama","LLAMA HEAVY CHAIN ANTIBODY D7","PF07686(V-set)",5,"SER A  29;MET A  34;VAL A  78;ALA A  94;TYR A 102","SO4 A1114 (-2.7A);None;None;None;None","0.76A","3qxvB-2xa3A:20.9","3qxvB-2xa3A:69.77"],["3QXV_B_MTXB2000_1","3g9a","Camelus dromedarius","MINIMIZER","PF07686(V-set)",6,"ALA B  24;MET B  34;ARG B  71;VAL B  78;ALA B  94;TYR B 102","None","0.69A","3qxvB-3g9aB:19.7","3qxvB-3g9aB:64.93"],["3QXV_B_MTXB2000_1","3if1","Mus musculus","IMMUNOGLOBULIN HEAVY CHAIN (IGG2A)","PF07654(C1-set);PF07686(V-set)",5,"VAL B   2;ALA B  24;MET B  34;ARG B  71;TYR B 102","None","0.74A","3qxvB-3if1B:19.6","3qxvB-3if1B:32.21"],["3QXV_B_MTXB2000_1","3k7u","Lama glama","ANTIBODY","PF07686(V-set)",5,"MET A  34;ARG A  72;VAL A  79;ALA A  98;TYR A 111","None","0.47A","3qxvB-3k7uA:22.2","3qxvB-3k7uA:73.81"],["3QXV_B_MTXB2000_1","3ln9","Camelidae","IMMUNOGLOBULIN HEAVY CHAIN ANTIBODY VARIABLE DOMAIN B10","PF07686(V-set)",6,"VAL A   2;ALA A  24;ARG A  72;VAL A  79;ALA A  98;TYR A 113","None;None;None;None;None;GOL A 137 (-4.8A)","0.92A","3qxvB-3ln9A:19.4","3qxvB-3ln9A:67.94"],["3QXV_B_MTXB2000_1","3qxu","Lama glama","ANTI-METHOTREXATE CDR1-3 GRAFT","PF07686(V-set)",6,"SER A  30;TRP A  34;MET A  36;VAL A  81;ALA A 100;TYR A 120","None","1.49A","3qxvB-3qxuA:24.1","3qxvB-3qxuA:96.03"],["3QXV_B_MTXB2000_1","3qxu","Lama glama","ANTI-METHOTREXATE CDR1-3 GRAFT","PF07686(V-set)",7,"SER A  31;TRP A  34;MET A  36;ARG A  74;VAL A  81;ALA A 100;TYR A 120","None","1.43A","3qxvB-3qxuA:24.1","3qxvB-3qxuA:96.03"],["3QXV_B_MTXB2000_1","3qxu","Lama glama","ANTI-METHOTREXATE CDR1-3 GRAFT","PF07686(V-set)",7,"VAL A   4;ALA A  26;SER A  30;MET A  36;VAL A  81;ALA A 100;TYR A 120","None","0.89A","3qxvB-3qxuA:24.1","3qxvB-3qxuA:96.03"],["3QXV_B_MTXB2000_1","3qxu","Lama glama","ANTI-METHOTREXATE CDR1-3 GRAFT","PF07686(V-set)",8,"VAL A   4;ALA A  26;SER A  31;MET A  36;ARG A  74;VAL A  81;ALA A 100;TYR A 120","None","0.91A","3qxvB-3qxuA:24.1","3qxvB-3qxuA:96.03"],["3QXV_B_MTXB2000_1","3qyc","Homo sapiens","VH DOMAIN OF IGG MOLECULE","PF07686(V-set)",5,"VAL A   4;ALA A  26;MET A  36;ARG A  74;VAL A  81","None","0.86A","3qxvB-3qycA:20.1","3qxvB-3qycA:61.42"],["3QXV_B_MTXB2000_1","3r0m","Lama glama","LLAMA VHH A12","PF07686(V-set)",5,"ALA A  24;SER A  29;MET A  34;VAL A  78;ALA A  94","None;SO4 A 131 (-2.7A);None;None;None","0.93A","3qxvB-3r0mA:21.4","3qxvB-3r0mA:70.54"],["3QXV_B_MTXB2000_1","3sge","Mus musculus","HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",5,"VAL H   2;ALA H  24;MET H  34;ARG H  74;TYR H 104","None","0.88A","3qxvB-3sgeH:20.1","3qxvB-3sgeH:37.20"],["3QXV_B_MTXB2000_1","3stb","Lama glama","SINGLE DOMAIN ANTIBODY VHH","PF07686(V-set)",5,"ALA A  26;MET A  36;ARG A  73;VAL A  80;ALA A  99","None","0.67A","3qxvB-3stbA:22.0","3qxvB-3stbA:70.77"],["3QXV_B_MTXB2000_1","4b41","Lama glama","ANTIBODY G7","PF07686(V-set)",5,"VAL A   2;ALA A  24;MET A  34;VAL A  78;ALA A  97","None","0.93A","3qxvB-4b41A:18.6","3qxvB-4b41A:72.44"],["3QXV_B_MTXB2000_1","4dka","Lama glama","SINGLE DOMAIN ANTIBODY VHH","PF07686(V-set)",6,"ALA A  24;MET A  34;ARG A  72;VAL A  79;ALA A  98;TYR A 116","None","0.75A","3qxvB-4dkaA:22.0","3qxvB-4dkaA:73.23"],["3QXV_B_MTXB2000_1","4dka","Lama glama","SINGLE DOMAIN ANTIBODY VHH","PF07686(V-set)",6,"ALA A  24;SER A  30;MET A  34;ARG A  72;VAL A  79;ALA A  98","None","1.39A","3qxvB-4dkaA:22.0","3qxvB-4dkaA:73.23"],["3QXV_B_MTXB2000_1","4eig","Lama glama","CA1698 CAMEL ANTIBODY FRAGMENT","PF07686(V-set)",6,"ALA B  24;MET B  34;ARG B  71;VAL B  78;ALA B  97;TYR B 106","None","0.71A","3qxvB-4eigB:20.1","3qxvB-4eigB:66.94"],["3QXV_B_MTXB2000_1","4fhb","Lama glama","NB179","PF07686(V-set)",5,"MET D  34;ARG D  72;VAL D  79;ALA D  98;TYR D 118","None","0.52A","3qxvB-4fhbD:21.2","3qxvB-4fhbD:71.32"],["3QXV_B_MTXB2000_1","4gft","Lama glama","NANOBODY","PF07686(V-set)",5,"MET B  36;ARG B  74;VAL B  81;ALA B 100;TYR B 115","None;None;None;None;PCA B   2 ( 3.9A)","0.35A","3qxvB-4gftB:22.2","3qxvB-4gftB:66.93"],["3QXV_B_MTXB2000_1","4hem","Lama glama","ANTI-BASEPLATE TP901-1 LLAMA VHH 02","PF07686(V-set)",6,"ALA E  24;MET E  34;ARG E  72;VAL E  79;ALA E  98;TYR E 112","None","0.68A","3qxvB-4hemE:22.9","3qxvB-4hemE:73.39"],["3QXV_B_MTXB2000_1","4hxa","Mus musculus","13D9 FAB HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",5,"VAL H   2;MET H  34;ARG H  71;VAL H  78;TYR H 102","None","0.88A","3qxvB-4hxaH:20.3","3qxvB-4hxaH:53.17"],["3QXV_B_MTXB2000_1","4krm","Lama glama","NANOBODY\/VHH DOMAIN 7D12","PF07686(V-set)",5,"ALA B  24;MET B  34;VAL B  79;ALA B  98;TYR B 113","None","0.71A","3qxvB-4krmB:23.4","3qxvB-4krmB:70.16"],["3QXV_B_MTXB2000_1","4krm","Lama glama","NANOBODY\/VHH DOMAIN 7D12","PF07686(V-set)",5,"MET B  34;ARG B  72;VAL B  79;ALA B  98;TYR B 113","None","0.38A","3qxvB-4krmB:23.4","3qxvB-4krmB:70.16"],["3QXV_B_MTXB2000_1","4krm","Lama glama","NANOBODY\/VHH DOMAIN 7D12","PF07686(V-set)",5,"SER B  29;MET B  34;VAL B  79;ALA B  98;TYR B 113","None","0.92A","3qxvB-4krmB:23.4","3qxvB-4krmB:70.16"],["3QXV_B_MTXB2000_1","4lde","Lama glama","CAMELID ANTIBODY FRAGMENT","PF07686(V-set)",5,"VAL B   2;MET B  34;ARG B  71;VAL B  78;TYR B 109","None","0.75A","3qxvB-4ldeB:19.2","3qxvB-4ldeB:68.55"],["3QXV_B_MTXB2000_1","4lhq","Vicugna pacos","CAMELID NANOBODY","PF07686(V-set)",5,"ALA B  24;SER B  28;MET B  34;ARG B  72;VAL B  79","None","0.90A","3qxvB-4lhqB:21.6","3qxvB-4lhqB:63.28"],["3QXV_B_MTXB2000_1","4nc1","Lama glama","A20.1 VHH","PF07686(V-set)",7,"VAL C   9;ALA C  31;MET C  41;ARG C  79;VAL C  86;ALA C 105;TYR C 119","None","0.93A","3qxvB-4nc1C:22.1","3qxvB-4nc1C:70.23"],["3QXV_B_MTXB2000_1","4nc2","Lama glama","B39 VHH","PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;ARG B  71;ALA B  97;TYR B 111","None","0.82A","3qxvB-4nc2B:22.8","3qxvB-4nc2B:70.16"],["3QXV_B_MTXB2000_1","4ouo","Gallus gallus","ANTI BLA G 1 SCFV","PF07686(V-set)",5,"VAL A 116;ALA A 138;MET A 148;ARG A 185;VAL A 192","None","0.92A","3qxvB-4ouoA:13.3","3qxvB-4ouoA:27.27"],["3QXV_B_MTXB2000_1","4p2c","Lama glama","NANOBODY 1, ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION","PF07686(V-set)",6,"VAL G   2;MET G  34;ARG G  71;VAL G  78;ALA G  97;TYR G 111","None","0.59A","3qxvB-4p2cG:18.9","3qxvB-4p2cG:70.97"],["3QXV_B_MTXB2000_1","4qlr","Lama glama","LLAMA NANOBODY N02 VH DOMAIN","PF07686(V-set)",5,"ALA A  24;ARG A  72;VAL A  79;ALA A  98;TYR A 113","None","0.78A","3qxvB-4qlrA:22.3","3qxvB-4qlrA:69.84"],["3QXV_B_MTXB2000_1","4qo1","Lama glama","NB139 NANOBODY AGAINST THE DNA-BINDING DOMAIN OF P53","PF07686(V-set)",6,"ALA A  25;MET A  35;ARG A  73;VAL A  80;ALA A  99;TYR A 113","None","0.62A","3qxvB-4qo1A:21.3","3qxvB-4qo1A:62.70"],["3QXV_B_MTXB2000_1","4tvs","Vicugna pacos","VHH DOMAIN BS-1","PF05609(LAP1C)",5,"ALA a  25;ARG a  73;VAL a  80;ALA a  99;TYR a 117","None","0.80A","3qxvB-4tvsa:22.3","3qxvB-4tvsa:72.87"],["3QXV_B_MTXB2000_1","4w6y","Lama glama","NANOBODY NBFEDF9","PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;VAL B  79;ALA B  98;TYR B 118","None","0.96A","3qxvB-4w6yB:21.0","3qxvB-4w6yB:69.47"],["3QXV_B_MTXB2000_1","4weu","Lama glama","ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION","PF07686(V-set)",6,"VAL D 802;ALA D 824;MET D 834;ARG D 872;ALA D 898;TYR D 910","None","0.69A","3qxvB-4weuD:22.1","3qxvB-4weuD:72.00"],["3QXV_B_MTXB2000_1","4x8j","Mus musculus","12F4 FAB HEAVY CHAIN","no annotation",5,"VAL H   2;MET H  34;ARG H  74;VAL H  81;TYR H 104","None;None;None;None;2PE H 302 ( 4.6A)","0.83A","3qxvB-4x8jH:15.4","3qxvB-4x8jH:33.82"],["3QXV_B_MTXB2000_1","4xt1","Vicugna pacos","NANOBODY 7","PF07686(V-set)",6,"VAL C   2;ALA C  24;MET C  34;VAL C  78;ALA C  97;TYR C 107","None","0.94A","3qxvB-4xt1C:18.9","3qxvB-4xt1C:68.75"],["3QXV_B_MTXB2000_1","4yga","Vicugna pacos","VHH-1B7","PF07686(V-set)",5,"VAL B   3;ALA B  25;ARG B  73;VAL B  80;ALA B  99","None","0.63A","3qxvB-4ygaB:20.2","3qxvB-4ygaB:60.32"],["3QXV_B_MTXB2000_1","4zfo","Mus musculus","J22.9-XI FAB, HEAVY CHAIN","no annotation",5,"VAL H   2;ALA H  24;MET H  34;ARG H  72;TYR H 109","None","0.90A","3qxvB-4zfoH:19.0","3qxvB-4zfoH:37.44"],["3QXV_B_MTXB2000_1","5a2k","Mus musculus","IG LAMBDA-1 CHAIN V REGION S43","PF07686(V-set)",6,"VAL H   2;ALA H  24;MET H  34;ARG H  71;VAL H  78;TYR H 102","None","0.80A","3qxvB-5a2kH:19.8","3qxvB-5a2kH:29.03"],["3QXV_B_MTXB2000_1","5aum","Rattus","HEAVY CHAIN OF FAB FRAGMENT","no annotation",6,"VAL H   2;ALA H  24;MET H  34;ARG H  71;VAL H  78;ALA H  94","None","0.70A","3qxvB-5aumH:19.7","3qxvB-5aumH:38.16"],["3QXV_B_MTXB2000_1","5b6f","Mus musculus","ANTI-LEUKOTRIENE C4 MONOCLONAL ANTIBODY IMMUNOGLOBULIN GAMMA1 HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",5,"VAL B  21;ALA B  43;MET B  53;ARG B  93;VAL B 100","None","0.74A","3qxvB-5b6fB:19.3","3qxvB-5b6fB:35.07"],["3QXV_B_MTXB2000_1","5fwo","Lama glama","NANOBODY","PF07686(V-set)",5,"VAL A   2;ALA A  24;MET A  34;VAL A  78;TYR A 102","None","0.91A","3qxvB-5fwoA:21.5","3qxvB-5fwoA:68.18"],["3QXV_B_MTXB2000_1","5fwo","Lama glama","NANOBODY","PF07686(V-set)",6,"VAL A   2;MET A  34;ARG A  71;VAL A  78;ALA A  94;TYR A 102","None","0.60A","3qxvB-5fwoA:21.5","3qxvB-5fwoA:68.18"],["3QXV_B_MTXB2000_1","5gxb","Vicugna pacos","NANOBODY","PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;VAL B  79;ALA B  98;TYR B 118","None","1.10A","3qxvB-5gxbB:20.7","3qxvB-5gxbB:68.42"],["3QXV_B_MTXB2000_1","5hm1","Lama glama","LAMA VHH ANTIBODY 2E7","PF07686(V-set)",5,"VAL A   2;ALA A  24;VAL A  78;ALA A  94;TYR A 102","None","0.64A","3qxvB-5hm1A:18.6","3qxvB-5hm1A:68.00"],["3QXV_B_MTXB2000_1","5hvf","Vicugna pacos","VHH-I83","PF07686(V-set)",5,"VAL B   2;ALA B  24;ARG B  70;VAL B  77;TYR B 108","None","0.88A","3qxvB-5hvfB:18.7","3qxvB-5hvfB:69.35"],["3QXV_B_MTXB2000_1","5hvf","Vicugna pacos","VHH-I83","PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;VAL B  77;ALA B  96;TYR B 108","None","1.01A","3qxvB-5hvfB:18.7","3qxvB-5hvfB:69.35"],["3QXV_B_MTXB2000_1","5iml","Camelidae","NANOBODY","PF07686(V-set)",5,"MET B  33;ARG B  71;VAL B  78;ALA B  97;TYR B 113","None","0.35A","3qxvB-5imlB:23.7","3qxvB-5imlB:75.40"],["3QXV_B_MTXB2000_1","5j1s","Vicugna pacos","VHH DOMAIN BS-2","PF07686(V-set)",5,"ALA C  25;MET C  35;ARG C  72;VAL C  79;ALA C  98","None","0.94A","3qxvB-5j1sC:19.4","3qxvB-5j1sC:66.17"],["3QXV_B_MTXB2000_1","5j1s","Vicugna pacos","VHH DOMAIN BS-2","PF07686(V-set)",6,"VAL C   3;ALA C  25;MET C  35;VAL C  79;ALA C  98;TYR C 112","None","0.74A","3qxvB-5j1sC:19.4","3qxvB-5j1sC:66.17"],["3QXV_B_MTXB2000_1","5j56","Vicugna pacos","VHH SINGLE CHAIN ANTIBODY V1C7","PF07686(V-set)",5,"ALA B  24;ARG B  76;VAL B  83;ALA B 102;TYR B 117","None","0.67A","3qxvB-5j56B:20.5","3qxvB-5j56B:67.18"],["3QXV_B_MTXB2000_1","5ja8","Lama glama","NANOBODY 2","PF07686(V-set)",5,"VAL B   3;ALA B  25;ARG B  73;VAL B  80;ALA B  99","None","0.69A","3qxvB-5ja8B:19.9","3qxvB-5ja8B:70.16"],["3QXV_B_MTXB2000_1","5jqh","Lama glama","NANOBODY60, NB60","no annotation",5,"MET D  34;ARG D  71;VAL D  78;ALA D  97;TYR D 108","None","0.88A","3qxvB-5jqhD:19.1","3qxvB-5jqhD:70.16"],["3QXV_B_MTXB2000_1","5kel","Homo sapiens","C2G4 VARIABLE FAB DOMAIN HEAVY CHAIN","PF07686(V-set)",5,"ALA H  24;MET H  34;ARG H  71;VAL H  78;TYR H 102","None","0.88A","3qxvB-5kelH:17.1","3qxvB-5kelH:51.15"],["3QXV_B_MTXB2000_1","5lhq","Vicugna pacos","CAMELID-DERIVED ANTIBODY FRAGMENT NB7","PF07686(V-set)",6,"VAL B   2;ALA B  24;ARG B  72;VAL B  79;ALA B  98;TYR B 122","None","0.54A","3qxvB-5lhqB:21.8","3qxvB-5lhqB:64.66"],["3QXV_B_MTXB2000_1","5lmj","Lama glama","NANOBODY","PF07686(V-set)",6,"ALA A  24;MET A  34;ARG A  71;VAL A  78;ALA A  94;TYR A 102","None","0.98A","3qxvB-5lmjA:20.4","3qxvB-5lmjA:73.23"],["3QXV_B_MTXB2000_1","5lmj","Lama glama","NANOBODY","PF07686(V-set)",6,"VAL A   2;ALA A  24;ARG A  71;VAL A  78;ALA A  94;TYR A 102","None","0.81A","3qxvB-5lmjA:20.4","3qxvB-5lmjA:73.23"],["3QXV_B_MTXB2000_1","5lwf","Lama glama","CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-G10S","no annotation",6,"VAL C   5;ALA C  27;MET C  37;ARG C  75;ALA C 101;TYR C 117","None;None;None;None;None;ACT C 202 (-4.4A)","0.74A","3qxvB-5lwfC:21.1","3qxvB-5lwfC:68.80"],["3QXV_B_MTXB2000_1","5lwf","Lama glama","CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-G10S","no annotation",6,"VAL C   5;MET C  37;ARG C  75;VAL C  82;ALA C 101;TYR C 117","None;None;None;None;None;ACT C 202 (-4.4A)","0.77A","3qxvB-5lwfC:21.1","3qxvB-5lwfC:68.80"],["3QXV_B_MTXB2000_1","5mwn","Lama glama","LLAMA NANOBODY RAISED AGAINST TSSK, NBK27","PF07686(V-set)",5,"VAL N   2;ALA N  24;ARG N  71;VAL N  78;ALA N  97","None","0.85A","3qxvB-5mwnN:18.2","3qxvB-5mwnN:67.46"],["3QXV_B_MTXB2000_1","5mwn","Lama glama","LLAMA NANOBODY RAISED AGAINST TSSK, NBK27","PF07686(V-set)",5,"VAL N   2;ALA N  24;MET N  34;VAL N  78;ALA N  97","None","0.86A","3qxvB-5mwnN:18.2","3qxvB-5mwnN:67.46"],["3QXV_B_MTXB2000_1","5o02","Vicugna pacos","NANOBODY (VHH) NANO-4","PF07686(V-set)",5,"VAL C   2;ALA C  24;ARG C  72;ALA C  98;TYR C 113","None","0.93A","3qxvB-5o02C:21.3","3qxvB-5o02C:68.55"],["3QXV_B_MTXB2000_1","5o02","Vicugna pacos","NANOBODY (VHH) NANO-4","PF07686(V-set)",5,"VAL C   2;MET C  34;ARG C  72;ALA C  98;TYR C 113","None","0.59A","3qxvB-5o02C:21.3","3qxvB-5o02C:68.55"],["3QXV_B_MTXB2000_1","5o04","Vicugna pacos","NANOBODY (VHH) NANO-26","PF07686(V-set)",5,"VAL E   2;ALA E  24;ARG E  71;VAL E  78;TYR E 104","None","0.83A","3qxvB-5o04E:18.5","3qxvB-5o04E:65.32"],["3QXV_B_MTXB2000_1","5o0w","Vicugna pacos","NB474","PF07686(V-set)",5,"VAL E   2;ALA E  24;ARG E  76;VAL E  83;TYR E 126","None","0.81A","3qxvB-5o0wE:20.4","3qxvB-5o0wE:64.96"],["3QXV_B_MTXB2000_1","5o8f","Lama glama","NANOBODY NB25","no annotation",5,"MET L  34;ARG L  72;VAL L  79;ALA L  98;TYR L 114","None","0.53A","3qxvB-5o8fL:21.6","3qxvB-5o8fL:68.46"],["3QXV_B_MTXB2000_1","5o8r","Erwinia amylovora","L-LYSINE 6-MONOOXYGENASE INVOLVED IN DESFERRIOXAMINE BIOSYNTHESIS","no annotation",5,"VAL A  33;SER A 136;VAL A 376;ALA A 149;TYR A   6","None","1.01A","3qxvB-5o8rA:undetectable","3qxvB-5o8rA:19.66"],["3QXV_B_MTXB2000_1","5u3j","Homo sapiens","DH511.1 HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",5,"VAL H   2;ALA H  24;MET H  34;ARG H  71;ALA H  94","None","0.85A","3qxvB-5u3jH:19.5","3qxvB-5u3jH:54.07"],["3QXV_B_MTXB2000_1","5uk4","Vicugna pacos","ANTI-VESICULAR STOMATITIS VIRUS N VHH","no annotation",5,"VAL p   2;ALA p  24;ARG p  72;ALA p  98;TYR p 114","None","0.98A","3qxvB-5uk4p:21.2","3qxvB-5uk4p:71.43"],["3QXV_B_MTXB2000_1","5uk4","Vicugna pacos","ANTI-VESICULAR STOMATITIS VIRUS N VHH","no annotation",6,"VAL p   2;MET p  34;ARG p  72;VAL p  79;ALA p  98;TYR p 114","None","0.73A","3qxvB-5uk4p:21.2","3qxvB-5uk4p:71.43"],["3QXV_B_MTXB2000_1","5ukb","Vicugna pacos","ANTI-VESICULAR STOMATITIS VIRUS N VHH","no annotation",5,"ALA d  24;ARG d  72;VAL d  79;ALA d  98;TYR d 113","None","0.77A","3qxvB-5ukbd:22.4","3qxvB-5ukbd:70.97"],["3QXV_B_MTXB2000_1","5vxj","Vicugna pacos","SINGLE-DOMAIN ANTIBODY JMK-E3","no annotation",6,"VAL B   2;MET B  34;ARG B  72;VAL B  79;ALA B  98;TYR B 108","None","0.79A","3qxvB-5vxjB:19.1","3qxvB-5vxjB:63.08"],["3QXV_B_MTXB2000_1","5vxl","Vicugna pacos","SINGLE-DOMAIN ANTIBODY JPS-G3","no annotation",5,"ALA B  24;MET B  34;ARG B  73;ALA B  99;TYR B 106","None","0.71A","3qxvB-5vxlB:20.1","3qxvB-5vxlB:66.41"],["3QXV_B_MTXB2000_1","5vxl","Vicugna pacos","SINGLE-DOMAIN ANTIBODY JPS-G3","no annotation",5,"MET B  34;ARG B  73;VAL B  80;ALA B  99;TYR B 106","None","0.57A","3qxvB-5vxlB:20.1","3qxvB-5vxlB:66.41"],["3QXV_B_MTXB2000_1","5w1g","Homo sapiens","CR1-07 FAB HEAVY CHAIN","no annotation",5,"VAL H   2;ALA H  24;MET H  34;ARG H  72;TYR H 113","None","0.88A","3qxvB-5w1gH:21.4","3qxvB-5w1gH:40.65"],["3QXV_B_MTXB2000_1","5wb1","Human betaherpesvirus 5;Lama glama","ENVELOPE PROTEIN US28, NANOBODY 7 FUSION PROTEIN","no annotation",6,"VAL A1002;ALA A1024;MET A1034;VAL A1078;ALA A1097;TYR A1107","None","1.00A","3qxvB-5wb1A:17.9","3qxvB-5wb1A:15.08"],["3QXV_B_MTXB2000_1","5wb2","synthetic construct","NANOBODY B1","no annotation",5,"ALA D  24;ARG D  72;VAL D  79;ALA D  98;TYR D 118","None","0.96A","3qxvB-5wb2D:18.6","3qxvB-5wb2D:68.29"],["3QXV_B_MTXB2000_1","5x0t","Mus musculus","6H8 FAB FRAGMENT HEAVY CHAIN","no annotation",6,"VAL A  21;ALA A  43;MET A  53;ARG A  93;VAL A 100;TYR A 124","None","0.85A","3qxvB-5x0tA:19.9","3qxvB-5x0tA:31.40"],["3QXV_B_MTXB2000_1","5yy5","-","-","no annotation",5,"VAL C   2;ALA C  24;MET C  34;ARG C  71;TYR C  97","None","0.89A","3qxvB-5yy5C:19.3","3qxvB-5yy5C:undetectable"],["3QXV_B_MTXB2000_1","6c5w","Escherichia coli","NANOBODY","no annotation",5,"VAL C   2;MET C  34;VAL C  78;ALA C  97;TYR C 107","None","0.87A","3qxvB-6c5wC:19.1","3qxvB-6c5wC:72.84"],["3QXV_B_MTXB2000_1","6dbe","Lama glama","NANOBODY VHH R303","no annotation",5,"ALA A  24;MET A  34;VAL A  79;ALA A  98;TYR A 107","None","0.72A","3qxvB-6dbeA:20.5","3qxvB-6dbeA:undetectable"],["3QXV_B_MTXB2000_1","6dbe","Lama glama","NANOBODY VHH R303","no annotation",6,"SER A  30;MET A  34;ARG A  72;VAL A  79;ALA A  98;TYR A 107","None","1.21A","3qxvB-6dbeA:20.5","3qxvB-6dbeA:undetectable"],["3QXV_B_MTXB2000_1","6dbe","Lama glama","NANOBODY VHH R303","no annotation",5,"VAL A   2;ALA A  24;MET A  34;VAL A  79;TYR A 107","None","0.84A","3qxvB-6dbeA:20.5","3qxvB-6dbeA:undetectable"],["3QXV_B_MTXB2000_1","6ehg","Lama glama","HC3NB1","no annotation",5,"ALA C  24;MET C  34;ARG C  72;VAL C  79;ALA C  98","None","0.74A","3qxvB-6ehgC:22.3","3qxvB-6ehgC:57.14"],["3QXV_B_MTXB2000_1","6ehg","Lama glama","HC3NB1","no annotation",5,"MET C  34;ARG C  72;VAL C  79;ALA C  98;TYR C 112","None","0.50A","3qxvB-6ehgC:22.3","3qxvB-6ehgC:57.14"],["3QXV_B_MTXB2000_1","6ey0","Lama glama","LLAMA NANOBODY NB01","no annotation",5,"MET E  34;ARG E  71;VAL E  78;ALA E  94;TYR E 102","None","0.78A","3qxvB-6ey0E:21.3","3qxvB-6ey0E:56.60"],["3QXV_B_MTXB2000_1","6g8r","Homo sapiens","SHORT-CHAIN VARIABLE FRAGMENT","no annotation",5,"VAL A   2;ALA A  24;MET A  34;ARG A  72;TYR A 108","None","0.99A","3qxvB-6g8rA:20.2","3qxvB-6g8rA:62.65"],["3QXV_B_MTXB2000_1","6gzp","Lama glama","NANOBODY","no annotation",6,"VAL A   2;ALA A  24;MET A  34;ARG A  71;ALA A  94;TYR A 102","None","0.83A","3qxvB-6gzpA:21.8","3qxvB-6gzpA:undetectable"],["3QXV_B_MTXB2000_1","8fab","Homo sapiens","IGG1-LAMBDA HIL FAB (HEAVY CHAIN)","PF07654(C1-set);PF07686(V-set)",5,"VAL B   2;ALA B  24;MET B  34;ARG B  72;TYR B 110","None","0.96A","3qxvB-8fabB:21.6","3qxvB-8fabB:59.52"]]